Resource Library
Do you know of a resource that would be a great addition to our collection? Let us know!
Search results
Frequently asked questions about Opill
Letter from Free the Pill coalition steering committee to Perrigo
“As cost remains the top challenge for consumer access, it is incumbent upon all of us to remain committed to eliminating barriers to contraceptive equity and to work as hard as we can to create a fair and equitable marketplace for all. Now, more than ever, we must prioritize contraceptive equity—and for Opill, that means fulfilling Perrigo’s promise to set an affordable price and establish a robust consumer assistance program that allows everyone to benefit from this groundbreaking advancement in reproductive health.”
— Free the Pill coalition steering committee
Comment from Ibis Reproductive Health on Request for Information: Coverage of Over-the-Counter Preventive Services
“OTC coverage is key to equitable access and in the case of contraceptive care, it is also a reproductive justice issue. We know that barriers to contraception fall harder on communities that experience systemic inequities due to structural racism, bias, and other forms of oppression, and it is imperative that policies are designed to break down these barriers, not uphold them.”
— Kelly Blanchard, Robyn Elliott, Victoria Nichols, and Britt Wahlin
Comment from Free the Pill coalition on Request for Information: Coverage of Over-the-Counter Preventive Services
“We urge the Administration to require insurance coverage of OTC contraception without a prescription requirement and without cost sharing. This is a vitally important path to ensuring the accessibility of Opill, particularly for those who face the most barriers to accessing reproductive health care.”
— Free the Pill coalition
Insurance coverage of OTC oral contraceptives: Lessons from the field
Centering the voices of transgender, nonbinary, gender expansive, and BIPOC communities
Progestin-only birth control pills: User experiences and potential for OTC access
Experiences of progestin-only pill users in the United States and attitudes toward over-the-counter access
Letter from Free the Pill coalition to FDA Commissioner Dr. Robert M. Califf
“The FDA must prioritize reviewing the first-ever application for an OTC birth control pill and announce a new date for the advisory committee meeting as soon as possible.”
— Free the Pill coalition